CSCI Research Brief

Cannabichromene (CBC)

Pollastro F, Caprioglio D, Del Prete D, et al. Cannabichromene. Natural Product Communications. 2018;13(9):1934578X1801300. doi:10.1177/1934578×1801300922 

What Is Cannabichromene (CBC)?

Cannabichromene (CBC, 1a) is one out of over 100 phytocannabinoids found in the Cannabis sativa L. plant; it also occurs in unrelated plants, such as the Rhododendron species and fungi. CBC has a diverse chemistry, and a rich pharmacological potential that is not very well-known compared to the other phytocannabinoids—such as cannabidiol (CBD) and delta-9 tetrahydrocannabinol (THC)— found in the cannabis plant. CBC was first isolated from the Cannabis sativa L. plant in 1966, two years before THC was initially isolated. CBC is considered one of the “big four” cannabinoids found in cannabis, along with delta-9 tetrahydrocannabinol (THC), cannabidiol (CBD), and cannabigerol (CBG). 

CBC’s concentration is much lower (i.e., 0.2% to 0.3%) than the other big four phytocannabinoids found in cannabis; its physical properties were originally thought to be an active crystalline compound, but CBC is a gum or an oil.   

Anti-Inflammatory Properties of CBC

CBC has been found to improve colitis, and lower inflammation-induced intestinal hypermobility in rodents; but neither TRPA1, an ion channel located on the plasma membrane of many human and animal cells, nor cannabinoid receptors were involved in this activity. 

CBC showed very strong anti-inflammatory effects in animals with paw edema, producing a more potent anti-inflammatory effect than oral phenylbutazone, a nonsteroidal anti-inflammatory drug.  

In a study aimed at evaluating the effectiveness of phytocannabinoids used in the treatment of acne, CBC along with other cannabinoids such as CBDV and THCV, were selected as the best treatment options to normalize excess sebaceous oil production—produced by pro-acne agents—alleviate inflammation, and lower proliferation. Although preliminary studies show that CBC has potential to effectively treat various types of inflammatory disorders, there is an overall limited amount of information available on the pharmacokinetics and metabolism of CBC. 
Link to article:×1801300922

General Disclaimer

Center for Scientific Cannabinoid Information (CSCI) has placed information, including links to other websites or content belonging to or originating from third parties, on this website as a service to the general public and for general informational and educational purposes only.  The information on this website is not intended to substitute particularized advice of specialists or qualified professionals.  No content on this website should ever be used as a substitute for direct advice from appropriate professionals or qualified specialists.  This website could include inaccuracies or typographical errors.  The materials on this website do not constitute medical advice, do not necessarily reflect the opinions of CSCI or any of its employees, agents, affiliates, or subsidiaries, and are not guaranteed to be correct, complete, or up‐to‐date.  The publications, articles, and information on this website are provided as is without warranty of any kind, either express or implied, regarding accuracy, adequacy, validity, reliability, availability, or completeness, and CSCI does not warrant, endorse, guarantee, or assume responsibility for the accuracy or reliability of any information included on this website from third-party websites linked through this website.  UNDER NO CIRCUMSTANCE SHALL CSCI HAVE ANY LIABILITY TO YOU FOR ANY LOSS OR DAMAGE OF ANY KIND INCURRED AS A RESULT OF THE USE OF THE INFORMATION CONTAINED ON THIS WEBSITE OR RELIANCE ON ANY SUCH INFORMATION PROVIDED ON THIS WEBSITE. YOUR USE OF THIS WEBSITE AND YOUR RELIANCE ON ANY INFORMATION ON THIS WEBSITE IS SOLELY AT YOUR OWN RISK.

You cannot copy content of this page